Oral S(+)-ketamine does not change visceral perception in health

Digestive Diseases and Sciences

Volumn 49, Issue 11-12, 2004, Pages 1745-1751

  Kuiken, Sjoerd D ^a   Van Den Berg, Sake J Th ^a   Tytgat, Guido N J ^a   Boeckxstaens, Guy E E ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Barostat; FGID; Human; Hypersensitivity; Ketamine; NMDA; Sensation; Visceral perception

Indexed keywords

KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO;

ADULT; ARTICLE; BAROSTAT; BLOATING; CLINICAL TRIAL; COMPLIANCE (PHYSICAL); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; FEMALE; HEALTH; HUMAN; HUMAN EXPERIMENT; MALE; MEAL; MEASUREMENT; NAUSEA; NORMAL HUMAN; PAIN THRESHOLD; PERCEPTION; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SATIETY; SCORING SYSTEM; SENSATION; STOMACH; STOMACH DISTENSION; STOMACH FUNDUS; STOMACH MOTILITY; STOMACH PRESSURE; STOMACH VOLUME; STOMACH WALL; VISCERA; VISCERAL PAIN; VISUAL ANALOG SCALE;

ADMINISTRATION, ORAL; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GASTRIC DILATATION; GASTROINTESTINAL TRACT; HUMANS; KETAMINE; MALE; PAIN; RECEPTORS, N-METHYL-D-ASPARTATE; SENSATION;

EID: 13644265628     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-004-9563-6     Document Type: Article

References (37)

1. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA: Functional bowel disorders and functional abdominal pain. Gut 45 (Suppl 2):II43-II47, 1999
2. Mayer EA, Gebhart GF: Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 107:271-293, 1994
3. Cervero F, Laird JM: Visceral pain. Lancet 353:2145-2148, 1999
4. Kirkup AJ, Brunsden AM, Grundy D: Receptors and transmission in the brain-gut axis: Potential for novel therapies. I. Receptors on visceral afferents. Am J Physiol 280:G787-G794, 2001
5. Bueno L, Fioramonti J, Garcia-Villar R: Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. III. Visceral afferent pathways: A source of new therapeutic targets for abdominal pain. Am J Physiol 278:G670-G676, 2000
6. Haley JE, Sullivan AF, Dickenson AH: Evidence for spinal N-methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat. Brain Res 518:218-226, 1990
7. Woolf CJ, Thompson SW: The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; Implications for the treatment of post-injury pain hypersensitivity states. Pain 44:293-299, 1991
8. Hewitt DJ: The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin J Pain 16:S73-S79, 2000
9. Coutinho SV, Meller ST, Gebhart GF: Intracolonic zymosan produces visceral hyperalgesia in the rat that is mediated by spinal NMDA and non-NMDA receptors. Brain Res 736:7-15, 1996
10. Ide Y, Maehara Y, Tsukahara S, Kitahata LM, Collins JG: The effects of an intrathecal NMDA antagonist (AP5) on the behavioral changes induced by colorectal inflammation with turpentine in rats. Life Sci 60:1359-1363, 1997
11. Ji Y, Traub RJ: Spinal NMDA receptors contribute to neuronal processing of acute noxious and nonnoxious colorectal stimulation in the rat. J Neurophysiol 86:1783-1791, 2001
12. McRoberts JA, Coutinho SV, Marvizon JC, Grady EF, Tognetto M, Sengupta JN, Ennes HS, Chaban VV, Amadesi S, Creminon C, Lanthorn T, Geppetti P, Bunnett NW, Mayer EA: Role of peripheral N-methyl-D-aspartate (NMDA) receptors in visceral nociception in rats. Gastroenterology 120:1737-1748, 2001
13. Oliver T, Laird JM: Differential effects of N-methyl-D-aspartate receptor blockade on nociceptive somatic and visceral reflexes. Pain 79:67-73, 1999
14. Kuiken SD, Lei A, Tytgat GN, Holman R, Boeckxstaens GE: Effect of the low-affinity, noncompetitive N-methyl-d-aspartate receptor antagonist dextromethorphan on visceral perception in healthy volunteers. Aliment Pharmacol Ther 16:1955-1962, 2002
15. Tortella FC, Pellicano M, Bowery NG: Dextromethorphan and neuromodulation: Old drug coughs up new activities. Trends Pharmacol Sci 10:501-507, 1989
16. Liu HT, Hollmann MW, Liu WH, Hoenemann CW, Durieux ME: Modulation of NMDA receptor function by ketamine and magnesium: Part I. Anesth Analg 92:1173-1181, 2001
17. Loftis JM, Janowsky A: The N-methyl-D-aspartate receptor subunit NR2B: Localization, functional properties, regulation, and clinical implications. Pharmacol Ther 97:55-85, 2003
18. Pfenninger EG, Durieux ME, Himmelseher S: Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers. Anesthesiology 96:357-366, 2002
19. Grant IS, Nimmo WS, Clements JA: Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth 53:805-810, 1981
20. Johnstone M: The prevention of ketamine dreams. Anaesth Intens Care 1:70-74, 1972
21. Azpiroz F, Malagelada J-R: Physiological variations in canine gastric tone measured by an electronic barostat. Am J Physiol 247:229-237, 1985
22. Zhou S, Bonasera L, Carlton SM: Peripheral administration of NMDA, AMPA or KA results in pain behaviors in rats. Neuroreport 7:895-900, 1996
23. Wei F, Wang GD, Kerchner GA, Kim SJ, Xu HM, Chen ZF, Zhuo M: Genetic enhancement of inflammatory pain by forebrain NR2B over-expression. Nat Neurosci 4:164-169, 2001
24. Traub RJ, Zhai Q, Ji Y, Kovalenko M: NMDA receptor antagonists attenuate noxious and nonnoxious colorectal distention-induced Fos expression in the spinal cord and the visceromotor reflex. Neuroscience 113:205-211, 2002
25. Zheng H, Kelly L, Patterson LM, Berthoud HR: Effect of brain stem NMDA-receptor blockade by MK-801 on behavioral and fos responses to vagal satiety signals. Am J Physiol 277:R1104-R1111, 1999
26. Thomson AM, West DC, Lodge D: An N-methylaspartate receptor-mediated synapse in rat cerebral cortex: A site of action of ketamine? Nature 313:479-481, 1985
27. White PF, Schuttler J, Shafer A, Stanski DR, Horai Y, Trevor AJ: Comparative pharmacology of the ketamine isomers. Studies in volunteers. Br J Anaesth 57:197-203, 1985
28. Fisher K, Coderre TJ, Hagen NA: Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage 20:358-373, 2000
29. Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg FM: Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 333:99-104, 1997
30. Olivar T, Laird JM: Differential effects of N-methyl-D-aspartate receptor blockade on nociceptive somatic and visceral reflexes. Pain 79:67-73, 1999
31. Castroman PJ, Ness TJ: Ketamine, an N-methyl-D-aspartate receptor antagonist, inhibits the spinal neuronal responses to distension of the rat urinary bladder. Anesthesiology 96:1410-1419, 2002
32. Craviso GL, Musacchio JM: High-affinity dextromethorphan binding sites in guinea pig brain. I. Initial characterization. Mol Pharmacol 23:619-628, 1983
33. Zhang TY, Jahng JW, Kim DG: Dextromethorphan increases tyrosine hydroxylase mRNA in the mesencephalon of adolescent rats. Neurosci Lett 309:85-88, 2001
34. Sivarao DV, Krowicki ZK, Abrahams TP, Hornby PJ: Vagally-regulated gastric motor activity: Evidence for kainate and NMDA receptor mediation. Eur J Pharmacol 368:173-182, 1999
35. Krowicki ZK, Sivarao DV, Abrahams TP, Hornby PJ: Excitation of dorsal motor vagal neurons evokes non-nicotinic receptor-mediated gastric relaxation. J Auton Nerv Syst 77:83-89, 1999
36. Jankovic SM, Milovanovic D, Matovic M, Iric-Cupic V: The effects of excitatory amino acids on isolated gut segments of the rat. Pharmacol Res 39:143-148, 1999
37. Willert RP, Hobson A, Woolf C, Thompson D, Aziz Q: The induction of central sensitization in a human model of visceral pain hypersensitivity is prevented by ketamine, an NMDA receptor antagonist. Gastroenterology 124:A368, 2003 (abstr)